Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial

医学 安慰剂 内科学 观察研究 阿尔茨海默病 生物标志物 随机对照试验 痴呆 人口 磁共振成像 疾病 评定量表 τ蛋白 正电子发射断层摄影术 肿瘤科 临床试验 中枢神经系统疾病 临床终点 儿科 临床痴呆评级 危险系数 氟脱氧葡萄糖 队列研究
作者
Adam Fleisher,Leanne M. Munsie,Michele Mancini,Yun‐Ju Cheng,Jiaying Guo,Hugh Norman Nuthall,Diana Otero Svaldi,Vikas Kotari,William Kielbasa,Michael L. Hutton,Mirosław Bryś,Dustin J. Mergott,Mark Mintun,Oskar Hansson
出处
期刊:JAMA [American Medical Association]
卷期号:336 (12): 1017-1017 被引量:7
标识
DOI:10.1001/jama.2026.12768
摘要

Importance: Inhibiting O-linked N-acetylglucosaminidase (OGA) is hypothesized to slow accumulation of aggregated, hyperphosphorylated tau and neurofibrillary tangle formation. Objective: To evaluate the efficacy and safety of the potent oral OGA inhibitor ceperognastat in early symptomatic Alzheimer disease (AD). Design, Setting, and Participants: This double-blind, randomized, placebo-controlled phase 2 study was conducted at 72 sites in 5 countries from September 2021 to August 2024, with a posttreatment observational extension period through May 2025. The primary outcome population comprised participants with early symptomatic AD and biomarker evidence of tau pathology, including low to medium baseline tau levels (excluding individuals with high levels), as measured by positron emission tomography (PET) with flortaucipir F18. Intervention: Participants were randomized 1:1:1 to receive once-daily, oral ceperognastat at doses of 0.75 mg (n = 110) or 3 mg (n = 108) or placebo (n = 108). Main Outcomes and Measures: The primary outcome was change in Integrated AD Rating Scale (iADRS) score. The success criterion was a 60% or greater probability of achieving greater than or equal to 25% slower progression vs placebo using a bayesian probabilistic disease progression model. The 6 secondary outcomes were Alzheimer's Disease Assessment Scale-Cognitive Subscale, 13-item version; Alzheimer's Disease Cooperative Study-Activities of Daily Living scale; Clinical Dementia Rating-Sum of Boxes; Mini-Mental State Examination; tau PET; and volumetric magnetic resonance imaging. Results: Of the 327 randomized participants (mean age, 73.4 years; 201 [61.5%] females), 259 (87 receiving ceperognastat 0.75 mg, 86 receiving ceperognastat 3 mg, and 86 receiving placebo) with low to medium baseline tau levels were included in the primary outcome population (mean age, 74.3 years; 161 [62.2%] females). In this population, no clinically meaningful benefit vs placebo was observed for the primary end point (iADRS score) at 100 weeks: posterior mean change from baseline was -8.39 with ceperognastat 0.75 mg, -13.27 with ceperognastat 3 mg, and -10.07 with placebo. The disease progression ratio relative to placebo was 0.84 (95% credible interval [CrI], 0.66-1.04) for the ceperognastat 0.75 mg group and 1.32 (CrI, 1.10-1.58) for the ceperognastat 3 mg group, corresponding to 16% less and 32% greater progression, respectively. No benefits were demonstrated for secondary clinical end points. From baseline to 76 weeks, least-squares mean change in standardized uptake value ratio on PET showed a statistically significantly smaller increase (P = .04) vs placebo only for the ceperognastat 3 mg group in the lateral temporal lobe. Volumetric magnetic resonance imaging showed less whole brain volume loss in participants treated with ceperognastat vs placebo (43.2% [ceperognastat 0.75 mg] and 49.5% [ceperognastat 3 mg] less vs placebo; both P < .001). The ceperognastat 3 mg group had more serious (ceperognastat 0.75 mg: n = 13 [12.0%]; ceperognastat 3 mg: n = 29 [26.4%]; placebo: n = 17 [15.7%]) and severe (ceperognastat 0.75 mg: n = 7 [6.5%]; ceperognastat 3 mg: n = 15 [13.6%]; placebo: n = 7 [6.5%]) treatment-emergent adverse events. Conclusions and Relevance: Ceperognastat did not slow disease progression of early symptomatic AD. Trial Registration: ClinicalTrials.gov Identifier: NCT05063539.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Sylvia发布了新的文献求助10
刚刚
luobeimin发布了新的文献求助10
刚刚
天生骄傲发布了新的文献求助10
刚刚
许木完成签到,获得积分10
刚刚
1秒前
1秒前
今后的应助被xxxxfiona采纳,获得10
1秒前
antares完成签到,获得积分10
1秒前
1秒前
世一上宙活完成签到,获得积分10
1秒前
1秒前
1秒前
gavincsu完成签到,获得积分10
2秒前
qazplm发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
3秒前
3秒前
3秒前
向日葵完成签到,获得积分10
3秒前
我是老大的应助被keyangouderic采纳,获得10
3秒前
琅冰冰完成签到,获得积分10
4秒前
科研通AI6.2的应助被baboon222采纳,获得10
4秒前
4秒前
5秒前
加速度发布了新的文献求助10
5秒前
顺心的尔白完成签到,获得积分10
5秒前
5秒前
甜甜玫瑰完成签到,获得积分0
5秒前
彭于晏的应助被实验室采纳,获得10
6秒前
null的应助被gavincsu采纳,获得10
6秒前
6秒前
7秒前
wbw完成签到 ,获得积分10
8秒前
8秒前
lmei完成签到 ,获得积分10
8秒前
风格的应助被糊涂的缘分采纳,获得30
8秒前
8秒前
NexusExplorer的应助被123采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153492
求助须知:如何正确求助?哪些是违规求助? 9550166
关于积分的说明 21696892
捐赠科研通 7742051
什么是DOI,文献DOI怎么找? 3425502
关于科研通互助平台的介绍 2550620
邀请新用户注册赠送积分活动 2469156